These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28617732)

  • 1. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
    Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    Wu JH; Wang TH; Huang JY; Su CC
    J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.
    Muz OE; Dagdelen K; Pirdal T; Guler M
    Int Ophthalmol; 2021 Nov; 41(11):3825-3835. PubMed ID: 34263385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH
    Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
    El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
    Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
    Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
    Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
    J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
    Kahook MY; Noecker R
    Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis.
    Suzuki K; Teranishi S; Sagara T; Yoshino H; Nakayama M; Enoki M; Nuno Y; Hirano S; Wakuta M; Takahashi N; Tokuhisa K; Kondo Y; Shiraishi R; Ishida Y; Sonoda KH;
    J Glaucoma; 2015 Aug; 24(6):e145-50. PubMed ID: 24240881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
    Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
    Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
    Kumar S; Singh T; Ichhpujani P; Vohra S
    Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost.
    Yamazaki S; Nanno M; Kimura T; Suzumura H; Yoshikawa K
    Jpn J Ophthalmol; 2010 Jan; 54(1):7-14. PubMed ID: 20151269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.